A randomized, double-blind, placebo-controlled, multicenter, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH)
Latest Information Update: 24 May 2024
At a glance
- Drugs Lanifibranor (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Proof of concept; Therapeutic Use
- Acronyms NATIVE
- Sponsors Inventiva Pharma
- 22 May 2024 According to Inventiva Pharma media release, data from the study will be presented as poster presentation at the upcoming International Liver Congress™ 2024 hosted by the European Association for the Study of the Liver (EASL) on June 5-8, 2024 in Milan, Italy.
- 13 May 2024 According to Inventiva Pharma media release, data from this trial published in the peer-reviewed scientific journal Nature Communications
- 13 May 2024 Results published in the Inventiva Pharma Media Release